Drug intelligence / Profile preview

Viralym-A

Development stage: Unknown
Lead developer: Kalaris Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Viralym-A is an investigational T cell immunotherapy developed by AlloVir (formerly ViraCyte) for the treatment of Adenovirus infections in immunocompromised patients, particularly those who have undergone allogeneic stem cell transplant. It consists of banked Adenovirus-specific T cells derived from healthy donors, designed to specifically target and eliminate life-threatening Adenovirus infections that can occur when the immune system is weakened post-transplant. The drug is an investigational product not yet approved by the Food and Drug Administration (FDA).

Targets

Adenovirus-derived peptide-HLA complex

Beyond the preview

Go deeper on Viralym-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viralym-A.

Explore the full profile